期刊文献+

壳聚糖修饰的L-天门冬酰胺酶脂质体的稳定性 被引量:2

Preliminary Study on the Stability of Chitosan-Modified Liposomes Containing L-Asparaginase
下载PDF
导出
摘要 考察壳聚糖修饰的L-天门冬酰胺酶脂质体在体外的稳定性。分别从最适pH、最适温度、储存稳定性、酸碱稳定性、热稳定性,以及抗胰蛋白酶水解的能力等方面,对比游离L-天门冬酰胺酶及壳聚糖修饰的L-天门冬酰胺酶脂质体。结果表明:游离L-天门冬酰胺酶和壳聚糖修饰的L-天门冬酰胺酶脂质体的最适pH分别为7.5和7.0,最适温度分别为60℃和50℃,壳聚糖修饰的L-天门冬酰胺酶脂质体的储存稳定性、酸碱稳定性、热稳定性,以及抗胰蛋白酶水解的能力均优于游离酶。因此,壳聚糖修饰的L-天门冬酰胺酶脂质体能明显提高游离酶的稳定性。 To investigate the in vitro stability of chitosan-modified liposomes containing L-asparaginase (LACL) ,the optimal pH,temperature,storage stability,pH stability,thermal stability and proteolytic stability were investigated in this study. The optimal pH values of L-ASP and LACL were at 7.5 and 7.0,respectively. The optimal temperatures of L-ASP and LACL were at 60 ℃ and 50 ℃ respectively. The stabilities of LACL were higher than that of L-ASP. The results shown that the stability of L-ASP was significantly enhanced by the LACL.
出处 《食品与生物技术学报》 CAS CSCD 北大核心 2016年第10期1041-1044,共4页 Journal of Food Science and Biotechnology
基金 国家自然科学基金项目(30973645)
关键词 L-天门冬酰胺酶 脂质体 壳聚糖 稳定性 L-asparaginase, liposome, chitosan, stability
  • 相关文献

参考文献3

二级参考文献24

  • 1孟尧,辛渝,谭晓晶,许晓燕,余彩霞,杨波,孟延发.朊圆酵母尿酸酶的基本特性研究[J].四川大学学报(自然科学版),2006,43(2):414-419. 被引量:6
  • 2Zheng Y, Fu LM, Qiu Y, et al. Enzymatic degradation of leuprolide in rat intestinal mucosal homogenates[ J ]. Pharm Dev Technol, 1999,4(3) :539.
  • 3Haviv F, Fitzpatrick TD, Nichols CJ, et al. Stabilization of the Nterminal residues of LHRH agonists and the effect on pharmacokinetics[J]. J Med Chem, 1992,35(21 ) :3890.
  • 4Adjei P, Sundberg D, Miller J, et al. Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans[J]. Pharm Res, 1992,9(2): 244.
  • 5Okada H, Inoue Y, Heya T, et al. Pharmacokinetics of once -a-month injectable microspheres of leuprolide acetate [J]. Pharm Res, 1991,8(6) :787.
  • 6Kroon A, Soekarjo M, Gier J, et al. The role of charge and hydrophobicity in peptide-lipid interaction: a comparative study based on tryptophan fluorescence measurements combined with the use of aqueous and hydrophobic quenchers[ J ]. Biochemistry, 1990,29 (36):8229.
  • 7Soulages JL, Arresc EL. Fluorescence spectroscopy of single tryptophan mutants of apolipophorin-Ⅲ in discoidal lipoproteins of dimyristoylphosphatidylcholine [ J ]. Biochemistry ,2000,39(34 ): 10574.
  • 8Ernst ME, Fravel MA. Febuxostat: a selective xanthine-oxidase / xanthine-dehydrogenase inhibitor for the management of hype- ruricemia in adults with gout [J]. Clin Ther, 2009, 31 (11): 2503-2518.
  • 9Lu W, Song K, Wang Y, et ol. Relationship between serum uric acid and metabolic syndrome: an analysis by structural equation modeling [J]. J Clin Lipidol, 2012, 6 (2): 159-167.
  • 10Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia [J]. Adv Drug Deliver Rev, 2008, 60 ( 1 ): 59-65.

共引文献23

同被引文献14

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部